SCHEMBL1044265

SCHEMBL1044265

COc1ccc(CCNc2cc(-c3c[nH]c4ncccc34)cc(Cl)n2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 18/20 0.72
ROCK2 O75116 18/20 0.72
PRKACA P17612 18/20 0.72
CDC7 O00311 18/20 0.72
HIPK2 Q9H2X6 17/20 0.72
PIM1 P11309 16/20 0.72
GSK3B P49841 16/20 0.72
CDK9 P50750 11/20 0.72
CDK7 P50613 10/20 0.72
IRAK4 Q9NWZ3 9/20 0.72
MAP4K4 O95819 12/20 0.68
CLK4 Q9HAZ1 12/20 0.68
CLK2 P49760 9/20 0.68
DYRK1A Q13627 9/20 0.68
DAPK3 O43293 8/20 0.68
PRKX P51817 8/20 0.68
PKN2 Q16513 8/20 0.68
STK17A Q9UEE5 8/20 0.68
CDK5 Q00535 8/20 0.68
PRKD3 O94806 7/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1044366 0.90 CDC7 (0.80) CDK2ROCK2PRKACACDC7HIPK2
SCHEMBL1044490 0.89 CDK2 (0.80) CDK2ROCK2PRKACACDC7HIPK2
SCHEMBL1042957 0.89 CDK2 (0.69) CDK2ROCK2PRKACACDC7HIPK2
SCHEMBL1040898 0.88 CDC7 (0.74) CDK2ROCK2PRKACACDC7HIPK2
SCHEMBL1043183 0.88 CDC7 (0.74) CDK2ROCK2PRKACACDC7HIPK2
SCHEMBL994275 0.85 CDC7 (0.72) CDK2ROCK2PRKACACDC7HIPK2
SCHEMBL1044971 0.84 CDC7 (1.00) CDK2ROCK2PRKACACDC7HIPK2
SCHEMBL1045804 0.83 ROCK2 (0.77) CDK2ROCK2PRKACACDC7HIPK2
SCHEMBL1045597 0.83 CDC7 (0.63) CDK2ROCK2PRKACACDC7HIPK2
SCHEMBL1045154 0.83 CDC7 (0.71) CDK2ROCK2PRKACACDC7HIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP claimed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US claimed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP claimed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO claimed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US claimed
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP disclosed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US disclosed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP disclosed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO disclosed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDK2 52/4885ROCK2 373/4885PRKACA 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.